Khiron Life Sciences Corp. announced full reimbursement by the NHS of costs associated to cannabis-based medication and clinic fees for a patient enrolled in Zerenia Clinics UK. The patient was referred to the team at Zerenia Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.

This ground-breaking step validates Khiron's scientific and data-driven approach to demonstrate the efficacy, safety and cost-effectiveness of CBMPs on the management of chronic conditions such as pain and anxiety. The Company, who continues to train doctors on the prescription of CBMPs, will be presenting its real-world evidence (RWE) at the upcoming International Congress on Clinical Trials on Cannabis to an international audience of medical doctors in London's Canary Wharf on mid-February.